ADMA Biologics Inc. – Trademark Portfolio

Entity Type: 03

ADMA Biologics Inc. holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. The portfolio also extends into Class 36 (Insurance & Financial) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include ASCENIV and ADVANTAGE IG. The owner is based in RAMSEY, NJ.

465 ROUTE 17 SOUTH PO BOX 317

RAMSEY, NJ 07446

7 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

ADMA Biologics Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (6 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

36
Insurance & Financial (1 filing)

Insurance; financial affairs; monetary affairs; real estate affairs

Frequently Asked Questions

How many trademarks does ADMA Biologics Inc. have?

ADMA Biologics Inc. has 7 U.S. trademarks filed with the USPTO. Of these, 2 registered, 5 abandoned.

What trademark classes does ADMA Biologics Inc. file in?

ADMA Biologics Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 36 (Insurance & Financial). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are ADMA Biologics Inc.'s most well-known trademarks?

ADMA Biologics Inc.'s registered trademark portfolio includes well-known marks such as ASCENIV and ADVANTAGE IG. These are among 2 currently registered trademarks in the portfolio.

What is ADMA Biologics Inc.'s trademark registration success rate?

ADMA Biologics Inc. has a 29% trademark registration rate, with 2 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.